Nykode Therapeutics

NYKD.OLPhase 2

Oslo, NorwayFounded 2006nykode.com

Nykode Therapeutics is a clinical-stage biopharma company founded in 2006, leveraging its proprietary Vaccibody™ platform to develop targeted immunotherapies for cancer and autoimmune diseases. Its lead candidate, VB10.16, is a potentially first-in-class, off-the-shelf therapeutic for HPV16-positive cancers. The company's strategy focuses on accelerating its pipeline, expanding its platform into new therapeutic areas like autoimmunity, and forming value-creating strategic partnerships with industry leaders.

Market Cap

$106.6M

Founded

2006

Focus

RNA & Gene TherapyVaccines

NYKD.OL · Stock Price

USD 3.1242.23 (-93.12%)

Historical price data

AI Company Overview

Technology Platform

The Vaccibody™ platform is a modular immunotherapy technology designed to specifically target antigens to Antigen Presenting Cells (APCs) to induce rapid, strong, and long-lasting immune responses.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
VB10.16 Immunotherapy (DNA vaccine)	High Grade Cervical Intraepithelial Neoplasia	Phase 1/2
VB10.2129 + VB10.2210	COVID-19	Phase 1/2
VB10.NEO	Solid Tumors, Adult	Phase 1

Funding History

Total raised: $212M

IPO$150MUndisclosedDec 18, 2020

Series B$52MFidelity Management & Research CompanyJun 15, 2020

Series A$10MKreos CapitalJun 15, 2017

Opportunities

Significant opportunities exist in expanding the Vaccibody™ platform beyond oncology into autoimmune diseases and novel therapeutic modalities.

The partnerships with Roche and Regeneron provide avenues for accelerated development and validation in large markets.

Success with its lead candidate, VB10.16, could establish a new standard of care in HPV16-positive cancers.

Risk Factors

Key risks include clinical trial failures for lead assets, intense competition in the immuno-oncology space, reliance on capital markets for funding as a pre-revenue company, and the inherent uncertainty of expanding its platform into new disease areas.

Execution of partnerships is also critical.

Competitive Landscape

Nykode competes with large pharma immuno-oncology products and biotech companies developing cancer vaccines and neoantigen therapies. Its differentiation is the targeted APC delivery of the Vaccibody™ platform, designed for potency and durability. Partnerships with Roche and Regeneron provide strategic validation and resources.

Publications

Pipeline